LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
LENZ Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.30+0.03 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $103.54M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 202.2% | -33.6% | |
| Return on assets | – | – | -31.5% | |
| Current ratio | – | 0.66 | 14.23 | |
| Diluted shares | – | 0M | 29M |
Where the cash went
Fiscal 2021 to 2025, five years combined
LENZ Therapeutics generated $329.77M from operations and spent $13.66M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$329.77M
Used
$13.66M
Capital expenditure$13.66M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-430.3%
×Asset turnover0.07×
×Equity multiplier1.07×
=Return on equity, FY2025-33.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -430.3% | 0.07× | 1.07× | -33.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$82.13M
- Cash generatingOperating cash flow above zero-$69.17M
- Return on assets improvedROA up on the prior year-70.7% → -38.1%
- Earnings backed by cashOperating cash flow above net income-$69.17M vs -$82.13M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose20.36 → 14.23
- No dilutionShare count did not rise21M → 29M
- Gross margin improvedGross margin up on the prior year– → 97.81%
- More efficientAsset turnover rose0.00 → 0.09